Transcept Pharmaceuticals Inc., of Point Richmond, Calif., is eliminating approximately 45 percent of its work force as it looks to conserve cash following the receipt of its second complete response letter from the FDA for insomnia drug Intermezzo (zolpidem tartrate sublingual tablet).